Organon (OGN) Capital Expenditures (2020 - 2026)
Organon (OGN) posted quarterly Capital Expenditures of $42.0 million for Q2 2026, up 7.69% year-over-year from $39.0 million in Q2 2025, and up 13.51% on a QoQ basis from $37.0 million in Q1 2026.
Organon (OGN) Capital Expenditures (2020 - 2026) Analysis & Trends
Organon has reported Capital Expenditures for 7 years, with the latest figure at $42.0 million in Q2 2026.
- Capital Expenditures for Q2 2026 came in at $42.0 million, up 7.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $170.0 million (up 1.19% YoY), and the FY2025 annual result was $162.0 million, down 7.43% from the prior year.
- Capital Expenditures rose to $42.0 million in Q2 2026, from $37.0 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $79.0 million in Q4 2023 and troughed at $32.0 million in Q2 2024.
- A 5-year average of $47.9 million and a median of $45.5 million in 2022 frame the typical range for Capital Expenditures.
- The widest annual swing landed in 2023, when Capital Expenditures soared 57.78%; it then slumped 54.93% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $63.0 million in 2022, then gained by 25.4% to $79.0 million in 2023, then tumbled by 30.38% to $55.0 million in 2024, then dropped by 18.18% to $45.0 million in 2025, then slipped by 6.67% to $42.0 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $42.0 million in Q2 2026, $37.0 million in Q1 2026, and $45.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.03 Bn | 632.27 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.62 Bn | 463.05 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 375.00 Bn | 367.85 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.31 Bn | 295.62 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 236.34 Bn | 222.35 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.09 Bn | 178.91 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.43 Bn | 147.73 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.25 Bn | 102.08 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 42.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.00 Mn |
| Jun 30, 2026 | 42.00 Mn |
| Mar 31, 2026 | 37.00 Mn |
| Mar 31, 2026 | 37.00 Mn |
| Dec 31, 2025 | 45.00 Mn |
| Dec 31, 2025 | 45.00 Mn |
| Sep 30, 2025 | 46.00 Mn |
| Sep 30, 2025 | 46.00 Mn |
| Jun 30, 2025 | 39.00 Mn |
| Jun 30, 2025 | 39.00 Mn |
| Mar 31, 2025 | 32.00 Mn |
| Mar 31, 2025 | 32.00 Mn |
| Dec 31, 2024 | 55.00 Mn |
| Dec 31, 2024 | 55.00 Mn |
| Sep 30, 2024 | 42.00 Mn |
| Sep 30, 2024 | 42.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Mar 31, 2024 | 46.00 Mn |
| Mar 31, 2024 | 46.00 Mn |